Tools & Resources

Helpful and informative resources for you

KEVEYIS Start Form

Easy to understand and easy to complete, the KEVEYIS Start Form is the first step in getting your patient started on KEVEYIS.

Download Now
Uncovering Periodic Paralysis genetic testing brochure

Uncovering Periodic Paralysis is a no-cost genetic testing program for patients and their family members who have symptoms of hyperkalemic or hypokalemic periodic paralysis.

Download Now
Prior Authorization Checklist

This checklist is a useful resource for ensuring the most common clinical criteria are met when submitting a prior authorization for your patient.

Download Now
Appeal Letter

This sample Appeal Letter offers you an example outline of support for coverage of KEVEYIS as medically necessary for a patient whose coverage has been denied.

Download Now
Appeal Letter — Formulary Exception

This sample Appeal Letter — Formulary Exception offers you an example outline of support for coverage of KEVEYIS as medically necessary for a patient who does not have the therapy on formulary.

Download Now
Letter of Medical Necessity

This sample Letter of Medical Necessity offers you an example outline of support for coverage of KEVEYIS. Be sure to modify and replace content in the letter as needed.

Download Now
PPP white papers written by experts

Strongbridge Biopharma sponsored a roundtable discussion featuring expert clinicians and researchers in the field of neuromuscular disorders. These experts then developed a series of white papers to help physicians identify and address the clinical challenges of PPP.

Primary Periodic Paralysis:

Helpful and informative resources for your patients

Uncovering Periodic Paralysis genetic testing brochure

Learn more about Uncovering Periodic Paralysis, a no-cost genetic testing program for patients and their family members who have symptoms of hyperkalemic or hypokalemic periodic paralysis.

Download Now
Primary Periodic Paralysis Daily Tracker & 3-Month Diary

Your patients can keep track of their attacks and treatment progress with the Daily Tracker & 3-Month Diary. Having them bring this information to their next appointment will help you have an informed conversation.

Download Now
Coping Strategies Brochures

Your patients may need help understanding possible side effects of KEVEYIS and symptoms of PPP. These brochures can help educate them about treatment-related side effects, as well as strategies for managing them. As always, you are their best source of advice. These brochures are simply educational tools.

Community support

An Online PPP Community

The Inspire online community connects patients and caregivers living with PPP. Members share stories of support on how they are living and thriving with PPP as well as valuable information.

Learn more

Advocacy partners

Muscular Dystrophy Association (MDA)

A nonprofit organization whose mission is to provide hope and answers to families living with diseases that take away muscle strength and mobility.

Learn more

Periodic Paralysis Association

The Periodic Paralysis Association is a nonprofit charitable corporation founded to foster awareness of the periodic paralyses, promote science-based information regarding this class of disorder, and champion the interests of the periodic paralysis community.

Learn more

Periodic Paralysis International

A mission-driven, independent and not-for-profit whose goal is to help create successful partnerships between physicians, researchers, and periodic paralysis patients in order to speed diagnosis and improve therapy and management strategies, thereby improving quality of life and clinical outcomes for patients.

Learn more
To get started on KEVEYIS, please call 844‑KEVEYIS (844‑538‑3947).

EXPAND

Indication

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

Important Safety Information

Contraindications
  • Hypersensitivity to dichlorphenamide or other sulfonamides
  • Concomitant use of KEVEYIS and high-dose aspirin
  • Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS
  • Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy
Warnings and Precautions

Hypersensitivity and Other Life-Threatening Reactions

  • Fatalities associated with the administration of sulfonamides have occurred because of adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
  • Pulmonary involvement can occur in isolation or as part of a systemic reaction.
  • Discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction.

Concomitant Use of Aspirin or Other Salicylates

  • Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic acidosis, which can increase the risk of salicylate toxicity.
  • Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin.
  • Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with caution and carefully monitor in patients receiving low-dose aspirin.

Hypokalemia

  • KEVEYIS increases potassium excretion and can cause hypokalemia.
  • The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, and theophylline).
  • Baseline and periodic measurements of serum potassium are recommended.
  • If hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correction of potassium levels.

Metabolic Acidosis

  • KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis.
  • Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis.
  • Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation.
  • Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended.
  • If metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS.

Falls

  • KEVEYIS increases the risk of falls; risk is greater in the elderly and with higher doses.
  • Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.
Pregnancy and Lactation

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.

Adverse Reactions

The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.